Success Metrics

Clinical Success Rate
85.7%

Based on 18 completed trials

Completion Rate
86%(18/21)
Active Trials
8(17%)
Results Posted
11%(2 trials)
Terminated
3(6%)

Phase Distribution

Ph phase_4
14
30%
Ph phase_1
3
6%
Ph phase_2
15
32%
Ph phase_3
4
9%
Ph not_applicable
7
15%

Phase Distribution

3

Early Stage

15

Mid Stage

18

Late Stage

Phase Distribution43 total trials
Phase 1Safety & dosage
3(7.0%)
Phase 2Efficacy & side effects
15(34.9%)
Phase 3Large-scale testing
4(9.3%)
Phase 4Post-market surveillance
14(32.6%)
N/ANon-phased studies
7(16.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

85.7%

18 of 21 finished

Non-Completion Rate

14.3%

3 ended early

Currently Active

8

trials recruiting

Total Trials

47

all time

Status Distribution
Active(14)
Completed(18)
Terminated(3)
Other(12)

Detailed Status

Completed18
unknown12
Not yet recruiting6
Recruiting5
Active, not recruiting3
Terminated3

Development Timeline

Analytics

Development Status

Total Trials
47
Active
8
Success Rate
85.7%
Most Advanced
Phase 4

Trials by Phase

Phase 13 (7.0%)
Phase 215 (34.9%)
Phase 34 (9.3%)
Phase 414 (32.6%)
N/A7 (16.3%)

Trials by Status

active_not_recruiting36%
completed1838%
not_yet_recruiting613%
recruiting511%
unknown1226%
terminated36%

Recent Activity

Clinical Trials (47)

Showing 20 of 47 trialsScroll for more
NCT06957002Phase 2

Bosentan in the Treatment of Giant Cell Arteritis

Not Yet Recruiting
NCT07569081Phase 2

A Study Evaluating the Efficacy and Safety of Momelotinib in Participants With Vacuoles, E1-enzyme, X-linked, Autoinflammatory, Somatic (VEXAS) Syndrome

Not Yet Recruiting
NCT07542314Phase 4

Study to Evaluate the Safety and Effectiveness of ELEVIDYS in Participants With Duchenne Muscular Dystrophy Treated in a Post-Marketing Setting

Not Yet Recruiting
NCT05379634Phase 2

A Study of Nipocalimab in Participants With Active Idiopathic Inflammatory Myopathies

Active Not Recruiting
NCT07518277Not Applicable

A Multicenter, Prospective, Randomized Controlled Study Comparing Glucocorticoid Combined With Sirolimus With Monotherapy of Glucocorticoid in the Treatment of Newly Diagnosed Mild Autoimmune Hemolytic Anemia

Not Yet Recruiting
NCT07340463Phase 2

The Efficacy and Safety of Biologics (Belimumab/ Telitacicept) Induction Therapy in Proliferative Lupus Nephritis Patients for 6 Months Compared With Mycophenolate Mofetil Treatment

Recruiting
NCT05679401Phase 3

A Study With Imlifidase in Anti-GBM Disease

Terminated
NCT06868290Phase 2

Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Severe Active GPA or MPA

Recruiting
NCT04520451Phase 2

Open Label Two-Arm Study to Evaluate Rilzabrutinib in IgG4-Related Disease Participants

Completed
NCT06673134

Prospective Cohort Establishment and Clinical Observation of Children With Crohn's Disease

Active Not Recruiting
NCT07152366Phase 4

Efficacy and Safety of Sequential Hormone Therapy and Tetuzumab Therapy in Patients With Moderate to Severe TAO in the Active Stage After Glucocorticoid Treatment.

Recruiting
NCT07152340Phase 4

The Safety and Efficacy of Sequential Hormone Therapy and IBI311 Therapy in Patients With Active Moderate to Severe TAO in the Initial Treatment.

Recruiting
NCT05197842Phase 1

Efficacy and Safety of Substitution of Glucocorticoid for BDB-001 Injection in Patients With Anti-neutrophil Cytoplasmic Antibody(ANCA)-Associated Vasculitis

Completed
NCT06607016Phase 2

A Clinical Trial With KJ103 in Anti-GBM Disease

Active Not Recruiting
NCT06904040Not Applicable

A Single-center Study of CM313 in Patients With Pemphigus

Not Yet Recruiting
NCT05291650Phase 4

Ultrasound-guided Injection of Glucocorticoid Into Infrapatellar Fat Pad in Patients With Knee Osteoarthritis

Completed
NCT06663943Phase 1

A Randomized Study on Pemphigus Treatment With Humanized CD38 Antibody CM313.

Not Yet Recruiting
NCT06468709Phase 4

A Trial on the Recurrence Free Survival Rate of Type I AIP With High-risk of Recurrence

Recruiting
NCT04042220

Glucocorticoids, Immunotherapy and Radiosurgery for Brain Metastases

Completed
NCT04738318Phase 4

Steroid Administration for Articular Fractures of the Elbow (SAFE Trial)

Terminated

Drug Details

Intervention Type
DRUG
Total Trials
47